TI
PRLD icon

Trexquant Investment’s Prelude Therapeutics PRLD Stock Holding History

Trexquant Investment’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,458
Closed -$242K – 1645
2021
Q4 		$242K Buy
+19,458
New +$317K 0.02% 1035

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Trexquant Investment's PRLD Position: Q1 2022 in Review

Trexquant Investment sold out of Prelude Therapeutics (PRLD) in Q1 2022, closing a stake of 19,458 shares — an estimated $242K sold.

Trexquant Investment first reported a position in PRLD in Q4 2021 and held it in 1 quarter. The position peaked at $242K in Q4 2021. 68 funds tracked by Wall St. Rank hold PRLD as of Q1 2022.

  • Trexquant Investment reported no remaining Prelude Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Trexquant Investment sold 19,458 Prelude Therapeutics shares in Q1 2022, an estimated $242K.
  • Trexquant Investment first reported a position in Prelude Therapeutics in Q4 2021 and held it in 1 quarter.
  • Trexquant Investment's Prelude Therapeutics position peaked at $242K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2022.

Based on Trexquant Investment's 13F filing for Q1 2022, filed 13 May 2022.